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Abstract
Introduction: Recently, several studies assessing the clinical efficacy of rituximab (RTX) in systemic sclerosis (SSc)
have reported encouraging results. We aimed at exploring whether RTX exerts its beneficial effects on fibrosis
through attenuation of platelet-derived growth factor receptor (PDGFR) pathway activation.
Methods: We immunohistochemically assessed skin biopsies obtained from eight patients with SSc prior to and 6
months following RTX treatment, three control SSc patients (at the same time points) and three healthy subjects.
We assessed the expression of platelet-derived growth factor, PDGFR and phosphorylated (activated) PDGFR.
Results: We found a strong correlation of PDGFRa and PDGFRb expression on spindle-like cells and collagen
deposition in SSc biopsies (r = 0.97 and r = 0.96 for PDGFRa and PDGFRb, respectively; P < 0.0001 for both),
indicating a strong link between PDGFR expression and fibrosis. Expression of PDGFRa and PDGFRb in the papillary
dermis significantly decreased following RTX administration (mean ± standard error of the mean at baseline vs. 6
months, respectively: PDGFRa, 42.05 ± 5.03 vs. 26.85 ± 3.00, P = 0.004; and PDGFRb, 37.14 ± 4.94 vs. 24.01 ± 3.27, P
= 0.012). Similarly, expression of phosphorylated PDGFRa and PDGFRb in the papillary dermis significantly
decreased following RTX administration (P = 0.006 and P = 0.013 for phospho-PDGFRa and phospho-PDGFRb,
respectively). No changes in platelet-derived growth factor tissue expression or serum levels were found following
RTX treatment.
Conclusion: RTX may favorably affect skin fibrosis through attenuation of PDGFR expression and activation, a
finding that supports a disease-modifying role of RTX in SSc. Large-scale, multicenter studies are needed to further
explore the efficacy of RTX in SSc.
Introduction
Systemic sclerosis (SSc) represents one of the most chal-
lenging and difficult to treat diseases for rheumatolo-
gists. During recent years there has been significant
progress towards a better understanding of the complex
pathogenesis of the disease; however, this progress has
not been translated into novel therapies. Treatment
options for patients with SSc are so far limited, while no
therapy has definitely shown disease-modifying proper-
ties. During the last few years, four studies - including
one from our research group - have assessed the poten-
tial clinical efficacy of rituximab (RTX) in patients with
SSc and have reported encouraging results [1-4]. The
rationale for the use of RTX in SSc is based on strong
experimental data suggesting a key role for B cells in
regulating the fibrotic process [5-9]. Patients treated
with RTX showed either an improvement of skin fibro-
sis or lung function or remained clinically stable; it
should be noted, however, that stabilization alone
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should be considered a positive outcome in this devas-
tating disease where patients tend to gradually worsen
over time. In three of those studies where skin biopsies
were performed, a significant histologic improvement in
terms of reduction of collagen deposition and myofibro-
blast score was reported [1,3,4], suggesting a potential
disease-modifying role of RTX in skin fibrosis.
RTX is a monoclonal antibody that targets and
depletes B cells but it is not known how this drug may
mediate its beneficial effect on fibrosis. Platelet-derived
growth factor (PDGF) is a pivotal mediator of fibrosis; it
has stimulatory effects on scleroderma fibroblasts by
enhancing their proliferation and increasing collagen
production [10]. PDGF signals through two structurally
similar tyrosine kinase receptors, platelet-derived growth
factor receptor (PDGFR)a and PDGFRb. PDGF leads to
homodimerization or heterodimerization of these recep-
tors and to phosphorylation of specific tyrosine residues.
In animal models, enhancement of PDGF signaling leads
to fibrosis [11,12]. Moreover agonistic autoantibodies
against PDGFR have been found in patients with SSc;
these stimulatory autoantibodies have been suggested to
participate in disease pathogenesis [13].
Based on these data, we aimed to explore whether
RTX exerts its beneficial effects on fibrosis through
attenuation of PDFGR pathway activation. We therefore
immunohistochemically assessed the expression of
PDGF, PDGFR and phospho-PDGFR, which represents
the phosphorylated and therefore active form of the
receptor. We report herein imunohistochemical evi-
dence that RTX treatment associates with a significant
decrease in PDGFR expression and activation in spin-
dle-like cells in the skin, indicating that RTX may favor-
ably affect fibrosis through modulation of PDGFR
expression/activation.
Materials and methods
Eight patients with diffuse SSc fulfilling the preliminary
American College of Rheumatology criteria for the clas-
sification of the disease [14] were enrolled. Demographic
and clinical characteristics of these patients have been
previously reported [1,15]. A local ethics committee
approved the study protocol (which fulfilled the Declara-
tion of Helsinki requirements) and written informed
consent was obtained from all participating individuals.
Skin histology
Patients were subjected to skin biopsies (a 5 mm punch
biopsy) prior to and 6 months following RTX adminis-
tration (consisting of four pulses of RTX (375 mg/m2)
weekly). Biopsies were taken from lesional skin in the
forearm; the second biopsy was taken from lesional skin
adjacent to (always < 2 cm) the site of the baseline
biopsy. Skin biopsies were also performed in the same
way and at the same time points in three SSc patients
who did not receive RTX therapy (two patients treated
with cyclophosphamide and one receiving no treatment).
Skin biopsies from three healthy subjects were used as
controls. All skin biopsies were fixed in 10% neutral buf-
fered formalin and embedded in paraffin.
Collagen deposition was assessed and quantified using
computerized image analysis as previously described [1].
Myofibroblasts (alpha smooth muscle actin-positive
cells) were detected by a standard streptavidin-biotin
peroxidase method using an anti-alpha smooth muscle
actin antibody (Novocastra, Newcastle, UK). For the
detection of PDGF-AA, PDGF-BB, PDGFRa, PDGFRb,
phospho-PDGFRa and phospho-PDGFRb we employed
a standard streptavidin-biotin peroxidase method
(DAKO Cytomation Envision™ Peroxidase DAB;DAKO,
Glostrup, Denmark), using the following antibodies:
anti-PDGF-AA (Millipore, Billerica, Massachusetts,
USA), anti-PDGF-BB (Acris, Herford, Germany), anti-
PDGFRa and anti-PDGFRb (both from Santa-Cruz Bio-
technology, Santa-Cruz, California, USA), anti-phospho-
PDFRa (phosphoY754; Abcam, Cambridge, UK), and
anti-phospho-PDFRb (phospho Y579; Abcam). The
same staining procedure was performed on paraffin sec-
tions from human hepatocellular carcinoma, which
served as a positive control for PDGFR and phospho-
PDGFR staining.
PDGFR and phospho-PDFR were mainly expressed in
spindle-like cells resembling fibroblasts, so we employed
a high-precision image analysis system (Image-Pro Plus
software program; Media Cybernetics, Silver Spring,
MD, USA) to quantify the intensity of immunohisto-
chemical staining in these cells, as previously described
[16-18]. We used a color camera (KY-F55MD; Olympus,
Tokyo, Japan) mounted on an Olympus BX 41F micro-
scope. Each time, before measurements of the images
were taken, we standardized the contrast and brightness
and calibrated the measurement system with appropriate
slides. The latter included the slides that we used as
positive controls in the immunohistochemical stains, as
were described above. We excluded the edges of the
sections from the evaluation.
For quantitation of immunostaining intensities, we
measured the inverse mean density based on the RGB
color parameter. The circle profile tool of the Image-Pro
Plus program was used for measurements of immunos-
taining of PDGFR and phospho-PDGFR in spindle-like
cells. According to previous reports [16,17], in each case
20 randomly selected color video images of 512 × 512
pixels with a resolution of 0.4348 μm were performed.
Measurements were made on a total of 100 cells per
specimen (5 cells/image ×20). Measurements were car-
ried out separately for spindle-like cells in the upper
and lower dermis. For each set of measurements, a
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curve was made according to immunostaining intensity.
The units arbitrarily ranged from 0 (intensity absent) to
230 (top intensity). In all immunohistochemical proce-
dures, for negative-control purposes, the same techni-
ques were used on tissue sections in which 1% BSA in
PBS substituted the primary antibody in each case. All
biopsies were evaluated simultaneously in a blinded (to
treatment and date) fashion. Serum levels of PDGF-AA
and PDGF-BB were measured by employing ELISA
methodology using commercially available kits (both
from R&D Systems, Minneapolis, MN, USA).
Statistical analysis
Statistical analysis was performed using the GraphPad
Prism software version 5 (GraphPad Software, La Jolla,
CA, USA). Pearson correlation and a paired t test were
used as indicated.
Results
Clinical and histological outcomes following RTX treat-
ment have been reported previously [1,15]. Briefly, we
found a significant improvement of skin thickening, as
clinically assessed, which coincided with histologic
improvement (reduction of collagen deposition and
myofibroblast score) in six out of eight patients. Histolo-
gic improvement was associated with depletion of skin-
infiltrating B cells.
PDGFR expression on spindle-like cells in scleroderma
skin is strongly associated with collagen deposition and
attenuates following rituximab administration
We first studied, by immunohistochemistry, the expres-
sion of PDGFRa and PDGFRb in scleroderma versus
normal skin. Expression of PDGFRa and PDGFRb could
not be detected in spindle-like cells in the dermis of
normal skin. A modest expression could be detected,
however, in vessels and adnexae. On the contrary,
PDGFRa and PDGFRb were highly expressed in sclero-
derma skin. Expression of PDGFRa and PDGFRb was
detected mainly in spindle-like cells resembling fibro-
blasts, in vessels and in adnexae.
We found a strong correlation of PDGFRa and
PDGFRb expression on spindle-like cells and collagen
deposition in SSc biopsies (r = 0.97 and r = 0.96 for
PDGFRa and PDGFRb, respectively; P < 0.0001 for
both), indicating a strong link between PDGFR expres-
sion and fibrosis. We also found a strong correlation
between alpha smooth muscle actin and PDGFR expres-
sion (r = 0.95, P = 0.0002 and r = 0.96, P = 0.0003 for
PDGFRa and PDGFRb, respectively) as shown in Figure
1, indicating that the majority of spindle-like cells were
probably myofibroblasts.
Expression of PDGFRa and PDGFRb in the papillary
dermis significantly decreased following RTX
administration (mean ± standard error of the mean
(SEM) at baseline vs. 6 months, respectively: PDGFRa,
42.05 ± 5.03 vs. 26.85 ± 3.00, P = 0.004; and PDGFRb,
37.14 ± 4.94 vs. 24.01 ± 3.27, P = 0.012). More specifi-
cally, expression of PDGFRa and PDGFRb decreased in
all six patients who showed histologic improvement but
remained unchanged in the two patients who did not
improve histologically, as shown in Figure 2. To explore
whether the decrease in PDGFR expression reported
above is a specific effect of RTX treatment, we studied
skin biopsies from three control patients with SSc. In
these three patients we found no change in the expres-
sion of PDGFRa and PDGFRb at 6 months in the papil-
lary dermis compared with baseline (mean ± SEM at
baseline vs. 6 months, respectively: PDGFRa, 35.77 ±
6.88 vs. 35.87 ± 3.69; and PDGFRb, 30.83 ± 6.85 vs.
33.17 ± 4.11; P = not significant in both cases). No
changes in PDGFR expression in the reticular dermis at
baseline versus 6 months was depicted in either the
RTX group or the control group.
PDGFR staining in vessels and adnexae was not
altered following RTX treatment, indicating that the
effect of B-cell depletion therapy was specific to spindle-
like cells.
The above data indicate that RTX mediates a signifi-
cant attenuation of PDGFRa and PDGFRb expression
on spindle-like cells in the papillary dermis of patients
with SSc.
Expression of phosphorylated (activated) PDGFR on
spindle-like cells in scleroderma skin decreases following
rituximab treatment
We next studied the expression of phosphorylated
PDGFRa and PDGFRb, which represent the activated
forms of the receptor. Staining patterns for phospho-
PDGFRa and phospho-PDGFRb were the same as for
PDGFRa and PDGFRb. Expression of phosphorylated
PDGFRa and PDGFRb could not be detected in spin-
dle-like cells in the dermis of normal skin; on the con-
trary, these receptors were highly expressed on spindle-
like cells in scleroderma skin.
Expression of phosphorylated PDGFRa and PDGFRb
in the papillary dermis significantly decreased following
RTX administration (mean ± SEM at baseline vs. 6
months, respectively: phospho-PDGFRa, 39.55 ± 5.16
vs. 24.21 ± 3.11, P = 0.006; and phospho-PDGFRb,
35.18 ± 4.97 vs. 22.09 ± 3.20, P = 0.013), as shown in
Figure 3. Representative histology is presented in Figure
4. On the contrary, we found no change in the expres-
sion of phosphorylated PDGFRa and PDGFRb at 6
months compared with baseline in the control SSc
patients (mean ± SEM at baseline vs. 6 months, respec-
tively: phospho-PDGFRa, 33.27 ± 7.21 vs. 33.63 ± 3.58;
and phospho-PDGFRb, 28.90 ± 6.92 vs. 31.07 ± 4.17; P
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Figure 1 Correlation between alpha smooth muscle actin and platelet-derived growth factor receptor expression. Immunohistochemical
expression of (A) alpha smooth muscle actin (aSMA), (B) platelet-derived growth factor receptor (PDGFR)a and (C) PDGFRb in spindle-like cells
in Patient 5 prior to rituximab treatment (streptavidin-biotin peroxidase ×100). Red arrow in the boxed area points to a spindle-like cell (among
others) expressing aSMA, PDGFRa and PDGFRb.
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= not significant in both cases). Representative histology
is presented in Figure 5. Images depicting phospho-
PDGFRb staining from all study subjects can be found
in Additional Files 1 to 8 (RTX-treated patients) and
Additional Files 9 to 11 (control patients).
We next calculated the phospho-PDGFRa/PDGFRa
ratio and the phospho-PDGFRb/PDGFRb ratio to assess
the phosphorylation (activation) status of the receptor.
We found that PDGFR on spindle-like cells is highly
phosphorylated in scleroderma skin, in sharp contrast to
Figure 2 Platelet-derived growth factor receptor expression and collagen deposition. Rituximab (RTX)-induced resolution of skin fibrosis
associates with attenuation of platelet-derived growth factor receptor (PDGFR) expression. RTX treatment mediates a significant decrease of (B)
PDGFRa and (C) PDGFRb expression on spindle-like cells in the papillary dermis, which associates with attenuation of collagen deposition (A).
No change in both PDGFR expression and collagen deposition was found in Patients 4 and 6, indicating a strong link between PDGFR
expression and fibrosis.
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normal skin where PDGFR and phospho-PDGFR are
virtually undetectable (mean ± SEM: 0.89 ± 0.02 and
0.93 ± 0.02 for phospho-PDGFRa/PDGFRa and phos-
pho-PDGFRb/PDGFRb, respectively). The ratios of
phospho-PDGFRa/PDGFRa and phospho-PDGFRb/
PDGFRb modestly declined following treatment with
RTX; statistical significance was reached only for phos-
pho-PDGFRb/PDGFRb (mean ± SEM at baseline vs. 6
months, respectively: phospho-PDGFRa/PDGFRa ratio,
0.92 ± 0.017 vs. 0.87 ± 0.02, P = 0.09; and phospho-
PDGFRb/PDGFRb ratio, 0.93 ± 0.009 vs. 0.89 ± 0.019, P
= 0.04).
The above data taken together indicate that RTX
treatment not only mediates a significant attenuation of
PDGFRa and PDGFRb expression on spindle-like cells,
but also associates with a decrease in PDGFRb phos-
phorylation (activation) status.
Figure 3 Expression of phosphorylated platelet-derived growth factor receptor in the papillary dermis following rituximab
administration. Rituximab (RTX) mediates a significant attenuation in platelet-derived growth factor receptor (PDGFR) phosphorylation
(activation) status. (A) Phospho-PDGFRa and (B) phospho-PDGFRb expression is decreased following RTX administration.
Figure 4 Phosphorylated platelet-derived growth factor receptor expression in the rituximab treated systemic sclerosis patients.
Substantial reduction of collagen accumulation following rituximab (RTX) treatment (B) compared with baseline (A) in Patient 2 (Masson’s
trichrome ×100). Immunohistochemical staining for phosphorylated platelet-derived growth factor receptor (PDGFR)a and PDGFRb in the same
patient prior to ((C) and (E), respectively) and following ((D) and (F), respectively) RTX treatment, where a significant decrease in phospho-
PDGFR staining can be seen (streptavidin peroxidase ×100). Red arrow in the boxed area points to a spindle-like cell (among others) expressing
phosphorylated PDGFRa and PDGFRb.
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Serum levels and tissue expression of PDGF is not altered
by rituximab treatment
We next assessed whether the attenuation of PDGFR
expression and activation reported above is mediated by
changes in serum levels or tissue expression of PDGF.
Serum levels of PDGF-AA and PDGF-BB did not
change following RTX treatment (mean ± SEM optical
density at baseline vs. 6 months, respectively: PDGF-AA,
0.68 ± 0.06 vs. 0.81 ± 0.09; and PDGF-BB, 0.32 ± 0.03
vs. 0.38 ± 0.09; P = not significant in both cases). Simi-
larly, we found no changes in the expression of PDGF
in the papillary dermis following RTX treatment (mean
± SEM at baseline vs. 6 months, respectively: PDGF-AA,
44.61 ± 3.63 vs. 47.06 ± 3.27; and PDGF-BB, 43.84 ±
5.44 vs. 44.59 ± 2.61; P = not significant in both cases).
These data suggest that the attenuation of PDGFR
expression/activation in scleroderma skin, following
RTX treatment, is not mediated by changes of its ligand
in either peripheral blood or skin.
Discussion
We report herein immunohistochemical evidence that
RTX treatment in patients with SSc associates with a
significant downregulation of PDGFRa and PDGFRb
expression on spindle-like cells in the skin and with
attenuation of the PDGFRb phosphorylation (activation)
status. The biologic effect of RTX on PDGFR is
noteworthy since PDGF and transforming growth factor
beta are considered master regulators of the fibrotic
process. An animal model with mutations in PDGFRa
leading to excessive kinase activity was created recently.
Interestingly, this animal model is characterized by a
multiorgan fibrotic disease that has striking similarities
with SSc [19]. Moreover, irradiation-induced lung fibro-
sis in mice associates with a significant increase in
PDGFR activation; blocking PDGFR signaling by specific
tyrosine kinase inhibitors attenuates fibrosis and
increases survival in these mice [20]. Blockade of
PDGFR signaling is also effective in other models, such
as the bleomycin-induced mouse model [21] and the
vanadium pentoxide-induced mouse model [22] of lung
fibrosis, providing evidence for the pivotal role of this
pathway. The central role of PDGFR signaling in fibrosis
is further supported by the reports of the antifibrotic
properties of imatinib mesylate, a kinase inhibitor that
partially acts through PDGFRb inhibition, in animal
models [23]. In patients with SSc, PDGF is highly
expressed in the skin [24], in bronchoalveolar lavage
fluid [25] as well as in peripheral blood [26].
In this study we found that PDGFR is highly phos-
phorylated (activated) in scleroderma skin, in sharp con-
trast to normal skin where phosphorylated PDGFR was
undetectable. This is the first study to report the expres-
sion of the phosphorylated form of PDGFR in SSc; other
Figure 5 Phosphorylated platelet-derived growth factor receptor expression in the control systemic sclerosis patients. Collagen
accumulation does not improve in a control patient following cyclophosphamide treatment (B) compared with baseline (A).
Immunohistochemical staining for phosphorylated platelet-derived growth factor receptor (PDGFR)a and PDGFRb in the same patient prior to
((C) and (E), respectively) and following ((D) and (F), respectively) rituximab (RTX) treatment, where no change in phospho-PDGFR staining can
be seen (streptavidin peroxidase ×100). Red arrow in the boxed area points to a spindle-like cell (among others) expressing phosphorylated
PDGFRa and PDGFRb.
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studies have assessed the expression of PDGFR using
antibodies not specific for the phosphorylated form of
the receptor [27-29]. The strong correlation between
PDGFR expression and collagen accumulation found in
our study underscores the significant role of PDGFR in
fibrosis. RTX induces a significant decrease in PDGFR
expression and collagen accumulation. This effect
seemed to be specific for RTX since PDGFR expression
was not decreased in the control biopsies.
This study does not answer the question of how RTX
affects the expression of PDGFR. One may hypothesize
that RTX may act through elimination of agonistic anti-
PDGFR autoantibodies. A direct answer to this question
could be given by measurement of these autoantibodies in
serum, prior to and following RTX administration, but
measurement of these autoantibodies can only be made
using complex and technically challenging bioassays.
Nevertheless, if RTX mediates its beneficial effect on fibro-
sis through elimination of stimulatory autoantibodies, one
would expect a more robust downregulation of PDGFRa
and PDGFRb phosphorylation (activation) status; on the
contrary, we found a significant decrease in PDGFRa and
PDGFRb expression and only a modest attenuation of
PDGFRb phosphorylation. We therefore propose that
other mechanisms may apply; RTX not only affects B cells
but has a broader effect on the immune system.
Conclusions
Data regarding the clinical efficacy of RTX in SSc are
encouraging. The Rituximab Group of the EULAR Sclero-
derma Trials and Research Group reported recently that
B-cell depletion therapy favorably affects skin fibrosis
(data derived from 72 SSc patients treated with RTX from
27 EULAR Scleroderma Trials and Research Group cen-
ters) [30]. The data reported herein suggest that RTX may
favorably affect skin fibrosis through attenuation of
PDGFR expression and activation, and add further evi-
dence in support of a disease-modifying role for RTX in
SSc. A large-scale, randomized controlled study assessing
the efficacy of RTX in SSc is therefore needed.
Additional material
Additional file 1: Phosphorylated PDGFRb expression in skin
biopsies from Patient 1 (rituximab treated). A and B, biopsy taken at
baseline; C and D, biopsy taken at 6 months. B and D, higher
magnification of the areas included in the boxes in A and C, respectively.
Red arrows indicate presence of spindle-like cells that express phospho-
PDGFRb. Streptavidin-biotin peroxidase: A and C, ×100; B and D, ×400.
Additional file 2: Phosphorylated PDGFRb expression in skin
biopsies from Patient 2 (rituximab treated). A and B, biopsy taken at
baseline; C and D, biopsy taken at 6 months. B and D, higher
magnification of the areas included in the boxes in A and C, respectively.
Red arrows indicate presence of spindle-like cells that express phospho-
PDGFRb. Streptavidin-biotin peroxidase: A and C, ×100; B and D, ×400.
Additional file 3: Phosphorylated PDGFRb expression in skin
biopsies from Patient 3 (rituximab treated). A and B, biopsy taken at
baseline; C and D, biopsy taken at 6 months. B and D, higher
magnification of the areas included in the boxes in A and C, respectively.
Red arrows indicate presence of spindle-like cells that express phospho-
PDGFRb. Streptavidin-biotin peroxidase: A and C, ×100; B and D, ×400.
Additional file 4: Phosphorylated PDGFRb expression in skin
biopsies from Patient 4 (rituximab treated). A and B, biopsy taken at
baseline; C and D, biopsy taken at 6 months. B and D, higher
magnification of the areas included in the boxes in A and C, respectively.
Red arrows indicate presence of spindle-like cells that express phospho-
PDGFRb. Streptavidin-biotin peroxidase: A and C, ×100; B and D, ×400.
Additional file 5: Phosphorylated PDGFRb expression in skin
biopsies from Patient 5 (rituximab treated). A and B, biopsy taken at
baseline; C and D, biopsy taken at 6 months. B and D, higher
magnification of the areas included in the boxes in A and C, respectively.
Red arrows indicate presence of spindle-like cells that express phospho-
PDGFRb. Streptavidin-biotin peroxidase: A and C, ×100; B and D, ×400.
Additional file 6: Phosphorylated PDGFRb expression in skin
biopsies from Patient 6 (rituximab treated). A and B, biopsy taken at
baseline; C and D, biopsy taken at 6 months. B and D, higher
magnification of the areas included in the boxes in A and C, respectively.
Red arrows indicate presence of spindle-like cells that express phospho-
PDGFRb. Streptavidin-biotin peroxidase: A and C, ×100; B and D, ×400.
Additional file 7: Phosphorylated PDGFRb expression in skin
biopsies from Patient 7 (rituximab treated). A and B, biopsy taken at
baseline; C and D, biopsy taken at 6 months. B and D, higher
magnification of the areas included in the boxes in A and C, respectively.
Red arrows indicate presence of spindle-like cells that express phospho-
PDGFRb. Streptavidin-biotin peroxidase: A and C, ×100; B and D, ×400.
Additional file 8: Phosphorylated PDGFRb expression in skin
biopsies from Patient 8 (rituximab treated). A and B, biopsy taken at
baseline; C and D, biopsy taken at 6 months. B and D, higher
magnification of the areas included in the boxes in A and C, respectively.
Red arrows indicate presence of spindle-like cells that express phospho-
PDGFRb. Streptavidin-biotin peroxidase: A and C, ×100; B and D, ×400.
Additional file 9: Phosphorylated PDGFRb expression in skin
biopsies from control Patient 1. A and B, biopsy taken at baseline; C
and D, biopsy taken at 6 months. B and D, higher magnification of the
areas included in the boxes in A and C, respectively. Red arrows indicate
presence of spindle-like cells that express phospho-PDGFRb. Streptavidin-
biotin peroxidase: A and C, ×100; B and D, ×400.
Additional file 10: Phosphorylated PDGFRb expression in skin
biopsies from control Patient 2. A and B, biopsy taken at baseline; C
and D, biopsy taken at 6 months. B and D, higher magnification of the
areas included in the boxes in A and C, respectively. Red arrows indicate
presence of spindle-like cells that express phospho-PDGFRb. Streptavidin-
biotin peroxidase: A and C, ×100; B and D, ×400.
Additional file 11: Phosphorylated PDGFRb expression in skin
biopsies from control Patient 3. A and B, biopsy taken at baseline; C
and D, biopsy taken at 6 months. B and D, higher magnification of the
areas included in the boxes in A and C, respectively. Red arrows indicate
presence of spindle-like cells that express phospho-PDGFRb. Streptavidin-
biotin peroxidase: A and C, ×100; B and D, ×400.
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